PE20091161A1 - Una vacuna multicomponente o monocomponente, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento - Google Patents
Una vacuna multicomponente o monocomponente, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimientoInfo
- Publication number
- PE20091161A1 PE20091161A1 PE2008001858A PE2008001858A PE20091161A1 PE 20091161 A1 PE20091161 A1 PE 20091161A1 PE 2008001858 A PE2008001858 A PE 2008001858A PE 2008001858 A PE2008001858 A PE 2008001858A PE 20091161 A1 PE20091161 A1 PE 20091161A1
- Authority
- PE
- Peru
- Prior art keywords
- procedure
- immunogen
- vaccine
- obtaining
- multicomponent
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 241000223109 Trypanosoma cruzi Species 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010001935 American trypanosomiasis Diseases 0.000 abstract 1
- 101710150192 Beta-secretase 1 Proteins 0.000 abstract 1
- 102100021257 Beta-secretase 1 Human genes 0.000 abstract 1
- 101710150190 Beta-secretase 2 Proteins 0.000 abstract 1
- 102100021277 Beta-secretase 2 Human genes 0.000 abstract 1
- 208000024699 Chagas disease Diseases 0.000 abstract 1
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract 1
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 abstract 1
- 101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 abstract 1
- 239000003228 hemolysin Substances 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 108010037277 thymic shared antigen-1 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
REFERIDA A UNA VACUNA MULTICOMPONENTE QUE COMPRENDE: a) UNA PORCION INMUNOGENICA CONFORMADA POR UNO O MAS POLIPEPTIDOS RECOMBINANTES, SINTETICOS O FRACCIONES DE ELLOS, Y b) UNO O MAS POLINUCLEOTIDOS QUE COMPRENDEN A LAS REGIONES QUE CODIFICAN A UNO O MAS POLIPEPTIDOS INMUNOGENICOS, DONDE AMBAS PORCIONES SON PARA DERIVADOS DE TRYPANOSOMA CRUZI. EL INMUNOGENO DE LA PORCION a) ES OBTENIDO DE AMASTIGOTES DE LOS PARASITOS TRYPANOSOMA CRUZI Y SE SELECCIONA DE PROTEINAS TSA-1, ASP-1, ASP-2, HEMOLISINA Y Lyt1. TAMBIEN ESTA REFERIDA A UNA VACUNA MONOCOMPONENTE, UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE OBTENCION DEL INMUNOGENO. DICHA VACUNA ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE CHAGAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP070104827A AR064593A1 (es) | 2007-10-31 | 2007-10-31 | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091161A1 true PE20091161A1 (es) | 2009-08-28 |
Family
ID=40591558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002770A PE20140520A1 (es) | 2007-10-31 | 2008-10-30 | Una vacuna multicomponente o monocomponente, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento |
| PE2008001858A PE20091161A1 (es) | 2007-10-31 | 2008-10-30 | Una vacuna multicomponente o monocomponente, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002770A PE20140520A1 (es) | 2007-10-31 | 2008-10-30 | Una vacuna multicomponente o monocomponente, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8900598B2 (es) |
| EP (1) | EP2206513B1 (es) |
| AR (1) | AR064593A1 (es) |
| BR (1) | BRPI0805753A2 (es) |
| CA (1) | CA2702534C (es) |
| CO (1) | CO6280407A2 (es) |
| CR (1) | CR11334A (es) |
| DO (1) | DOP2010000083A (es) |
| EC (1) | ECSP10010055A (es) |
| ES (1) | ES2569943T3 (es) |
| GT (1) | GT201000066A (es) |
| HN (1) | HN2010000750A (es) |
| MX (1) | MX2010004626A (es) |
| NI (1) | NI201000071A (es) |
| PA (1) | PA8816401A1 (es) |
| PE (2) | PE20140520A1 (es) |
| UY (1) | UY31451A1 (es) |
| WO (1) | WO2009056965A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
| WO2011031317A2 (en) * | 2009-09-10 | 2011-03-17 | The Board Of Regents Of The University Of Texas System | Vaccine for control of trypanosoma cruzi infection and chagas disease |
| WO2013011184A2 (es) | 2011-07-21 | 2013-01-24 | Consejo Superior De Investigaciones Científicas (Csic) | Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes |
| US10279023B2 (en) | 2013-09-24 | 2019-05-07 | Board Of Regents, The University Of Texas System | Mucin-associated surface protein as a vaccine against chagas disease |
| WO2015048072A2 (en) * | 2013-09-24 | 2015-04-02 | Board Of Regents, The University Of Texas System | Mucin-associated surface protein as vaccine against chagas disease |
| WO2016209598A1 (en) * | 2015-06-23 | 2016-12-29 | Saint Louis University | Peptides for inducing chagas disease responses |
| BR102021010469A2 (pt) * | 2021-05-28 | 2022-12-13 | Fundação Oswaldo Cruz | Proteína quimérica recombinante, seu uso, e, composição |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0586687A4 (en) | 1992-03-25 | 1996-04-17 | Univ New York | Trans-sialidase and methods of use and making thereof |
| US6875584B1 (en) | 1999-03-02 | 2005-04-05 | University Of Georgia Research Foundation, Inc. | Prophylactic and therapeutic immunization against protozoan infection and disease |
| US7060676B2 (en) * | 1999-12-20 | 2006-06-13 | Trustees Of Tufts College | T. cruzi-derived neurotrophic agents and methods of use therefor |
| US7780969B2 (en) | 2005-07-15 | 2010-08-24 | University Of Georgia Research Foundation, Inc. | Trypanosoma cruzi proteome compositions and methods |
| MX2008011632A (es) | 2006-03-17 | 2008-10-17 | Vib Vzw | Vacuna novedosa contra infeccion de trypanosoma cruzi. |
| AR064593A1 (es) * | 2007-10-31 | 2009-04-15 | Baeremaecker Barros Carlos De | Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento. |
-
2007
- 2007-10-31 AR ARP070104827A patent/AR064593A1/es unknown
-
2008
- 2008-10-30 ES ES08844056.5T patent/ES2569943T3/es active Active
- 2008-10-30 CA CA2702534A patent/CA2702534C/en not_active Expired - Fee Related
- 2008-10-30 PE PE2013002770A patent/PE20140520A1/es active IP Right Grant
- 2008-10-30 US US12/740,393 patent/US8900598B2/en not_active Expired - Fee Related
- 2008-10-30 WO PCT/IB2008/002923 patent/WO2009056965A2/es active Application Filing
- 2008-10-30 PE PE2008001858A patent/PE20091161A1/es not_active Application Discontinuation
- 2008-10-30 EP EP08844056.5A patent/EP2206513B1/en not_active Not-in-force
- 2008-10-30 MX MX2010004626A patent/MX2010004626A/es active IP Right Grant
- 2008-10-31 UY UY31451A patent/UY31451A1/es not_active Application Discontinuation
- 2008-10-31 BR BRPI0805753-2A patent/BRPI0805753A2/pt not_active Application Discontinuation
-
2009
- 2009-02-19 PA PA20098816401A patent/PA8816401A1/es unknown
-
2010
- 2010-03-15 DO DO2010000083A patent/DOP2010000083A/es unknown
- 2010-03-23 GT GT201000066A patent/GT201000066A/es unknown
- 2010-03-24 CR CR11334A patent/CR11334A/es unknown
- 2010-03-26 EC EC2010010055A patent/ECSP10010055A/es unknown
- 2010-04-21 HN HN2010000750A patent/HN2010000750A/es unknown
- 2010-04-26 NI NI201000071A patent/NI201000071A/es unknown
- 2010-05-18 CO CO10058905A patent/CO6280407A2/es unknown
-
2014
- 2014-10-31 US US14/529,454 patent/US9662378B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 US US15/492,365 patent/US10213500B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170290896A1 (en) | 2017-10-12 |
| WO2009056965A2 (es) | 2009-05-07 |
| CA2702534C (en) | 2016-10-18 |
| MX2010004626A (es) | 2010-10-04 |
| UY31451A1 (es) | 2009-05-29 |
| PA8816401A1 (es) | 2009-09-17 |
| US10213500B2 (en) | 2019-02-26 |
| EP2206513B1 (en) | 2016-02-17 |
| ECSP10010055A (es) | 2010-06-29 |
| HN2010000750A (es) | 2013-08-19 |
| US8900598B2 (en) | 2014-12-02 |
| PE20140520A1 (es) | 2014-05-05 |
| BRPI0805753A2 (pt) | 2012-04-17 |
| ES2569943T3 (es) | 2016-05-13 |
| CO6280407A2 (es) | 2011-05-20 |
| CA2702534A1 (en) | 2009-05-07 |
| US9662378B2 (en) | 2017-05-30 |
| US20100297186A1 (en) | 2010-11-25 |
| EP2206513A2 (en) | 2010-07-14 |
| WO2009056965A3 (es) | 2009-07-23 |
| CR11334A (es) | 2010-05-26 |
| DOP2010000083A (es) | 2010-07-15 |
| AR064593A1 (es) | 2009-04-15 |
| US20150056243A1 (en) | 2015-02-26 |
| GT201000066A (es) | 2012-04-03 |
| NI201000071A (es) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091161A1 (es) | Una vacuna multicomponente o monocomponente, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento | |
| CO2019010524A2 (es) | Plataforma de identificación de péptidos inmunogénicos basada en población | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| NI200700158A (es) | Agonistas glp-1, composiciones, métodos y usos | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| PE20150200A1 (es) | Formulacion de anticuerpos | |
| BR112016023979A2 (pt) | métodos de melhora ou aceleração da recuperação física após cirurgia para fratura óssea | |
| PE20130324A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| BR112015020804A2 (pt) | dispositivo fototerapeutico, método e uso | |
| NI200700260A (es) | Antagonistas de npy, preparación y usos. | |
| CY1115926T1 (el) | Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης | |
| AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| CO7240399A2 (es) | Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos | |
| PE20151871A1 (es) | Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos | |
| UY30820A1 (es) | Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos | |
| AR089068A1 (es) | Composiciones para el cuidado del cabello que contiene un polimero de aminosilicona | |
| CL2015000818A1 (es) | Compuestos derivados de n-prop-2-inil carboxamida, antagonistas del receptor transitorio potencial de la subfamilia 1, miembro 1 (trpa1); composicion farmaceutica que los comprende; y metodo para el tratamiento del dolor neuropatico, dolor por polineuropatia diabetica, dolor postoperatorio y dolor por cancer, entre otros. | |
| CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| BR112017018017A2 (pt) | composição de vacina compreendendo uma proteína imunogênica e adjuvantes de combinação para uso na promoção de respostas de células t específicas de antigenos | |
| AR101656A1 (es) | Materiales biofotónicos a base de silicona y usos de los mismos | |
| BR112015012842A2 (pt) | diazol lactamas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |